Total Payments
$510,976
2024 Payments
$12,089
Companies
25
Transactions
852
Medicare Patients
1,142
Medicare Billing
$41,574
Payment Breakdown by Category
Consulting$226,957 (44.4%)
Research$109,742 (21.5%)
Travel$82,068 (16.1%)
Other$71,949 (14.1%)
Food & Beverage$20,177 (3.9%)
Education$81.71 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $226,957 | 54 | 44.4% |
| Unspecified | $109,742 | 40 | 21.5% |
| Travel and Lodging | $82,068 | 116 | 16.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $71,949 | 31 | 14.1% |
| Food and Beverage | $20,177 | 607 | 3.9% |
| Education | $81.71 | 4 | 0.0% |
Payments by Type
General
$401,234
812 transactions
Research
$109,742
40 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $183,416 | 225 | $0 (2024) |
| Gilead Sciences, Inc. | $113,278 | 212 | $0 (2024) |
| Janssen Research & Development, LLC | $105,636 | 36 | $0 (2019) |
| Merck Sharp & Dohme LLC | $62,307 | 117 | $0 (2023) |
| Theratechnologies Inc. | $12,984 | 14 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $11,081 | 25 | $0 (2021) |
| GlaxoSmithKline, LLC. | $10,646 | 11 | $0 (2018) |
| EMD Serono, Inc. | $4,266 | 36 | $0 (2024) |
| AstraZeneca UK Limited | $4,107 | 4 | $0 (2018) |
| Janssen Biotech, Inc. | $1,276 | 80 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,089 | 20 | ViiV Healthcare Company ($8,449) |
| 2023 | $19,647 | 40 | ViiV Healthcare Company ($16,222) |
| 2022 | $61,634 | 38 | ViiV Healthcare Company ($55,945) |
| 2021 | $21,433 | 33 | ViiV Healthcare Company ($11,803) |
| 2020 | $18,368 | 27 | ViiV Healthcare Company ($16,920) |
| 2019 | $73,757 | 160 | ViiV Healthcare Company ($24,810) |
| 2018 | $160,905 | 254 | Gilead Sciences, Inc. ($39,887) |
| 2017 | $143,141 | 280 | Janssen Research & Development, LLC ($61,487) |
All Payment Transactions
852 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $34.40 | General |
| 08/28/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $147.43 | General |
| Category: HIV | ||||||
| 07/30/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $154.98 | General |
| Category: Neuropsychiatry | ||||||
| 07/09/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $7.25 | General |
| 06/24/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $6.74 | General |
| 05/16/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $134.33 | General |
| Category: HIV | ||||||
| 05/09/2024 | ViiV Healthcare Company | — | Travel and Lodging | In-kind items and services | $32.76 | General |
| 04/22/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $7.07 | General |
| 04/20/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $27.93 | General |
| Category: HIV | ||||||
| 04/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $7.12 | General |
| 03/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $7.27 | General |
| 03/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $92.00 | General |
| 03/05/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $22.62 | General |
| Category: HIV | ||||||
| 03/04/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $114.69 | General |
| 03/04/2024 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $42.79 | General |
| Category: HIV | ||||||
| 02/14/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $25.11 | General |
| Category: HIV | ||||||
| 01/17/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $121.87 | General |
| Category: HIV | ||||||
| 01/15/2024 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,280.00 | General |
| 01/12/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $22.52 | General |
| Category: HIV | ||||||
| 01/02/2024 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $7,800.00 | General |
| 12/12/2023 | ViiV Healthcare Company | CABENUVA (Biological) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: HIV | ||||||
| 12/12/2023 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $5.85 | General |
| Category: HIV | ||||||
| 11/15/2023 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $22.74 | General |
| Category: Neuropsychiatry | ||||||
| 11/14/2023 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $159.43 | General |
| Category: Neuropsychiatry | ||||||
| 11/07/2023 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $25.12 | General |
| Category: HIV | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor Combined With Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically-suppressed, Human Immunodeficiency Virus Type 1 Infected Subjects | Janssen Research & Development, LLC | $40,920 | 13 |
| A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once-daily Single-tablet Regimen Versus Continuing the Current Regimen | Janssen Research & Development, LLC | $30,869 | 7 |
| A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicistat Fixed Dose Combination Coadministered With Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 Infected Subjects | Janssen Research & Development, LLC | $27,538 | 11 |
| A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicistat Fixed Do | Janssen Research & Development, LLC | $6,308 | 5 |
| A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia | AstraZeneca UK Limited | $4,107 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 153 | 246 | $24,484 | $7,643 |
| 2022 | 14 | 213 | 309 | $29,143 | $8,676 |
| 2021 | 19 | 404 | 573 | $40,372 | $14,169 |
| 2020 | 15 | 372 | 455 | $34,688 | $11,086 |
Total Patients
1,142
Total Services
1,583
Medicare Billing
$41,574
Procedure Codes
57
All Medicare Procedures & Services
57 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 87536 | Detection test by nucleic acid for hiv-1 virus, quantification | Office | 2023 | 14 | 21 | $6,300 | $1,751 | 27.8% |
| 87591 | Detection test by nucleic acid for neisseria gonorrhoeae (gonorrhoeae bacteria), amplified probe technique | Office | 2023 | 16 | 43 | $4,300 | $1,479 | 34.4% |
| 87491 | Detection test by nucleic acid for chlamydia trachomatis, amplified probe technique | Office | 2023 | 16 | 41 | $4,100 | $1,410 | 34.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 18 | 22 | $3,190 | $1,398 | 43.8% |
| 90480 | Admn sarscov2 vacc 1 dose | Office | 2023 | 17 | 17 | $850.00 | $757.35 | 89.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 29 | 38 | $684.00 | $319.20 | 46.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 18 | 26 | $3,250 | $269.10 | 8.3% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 11 | 16 | $1,040 | $209.92 | 20.2% |
| 81003 | Automated urinalysis test | Office | 2023 | 14 | 22 | $770.00 | $48.40 | 6.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 13 | 15 | $2,775 | $1,470 | 53.0% |
| 87491 | Detection test by nucleic acid for chlamydia trachomatis, amplified probe technique | Office | 2022 | 12 | 41 | $4,100 | $1,424 | 34.7% |
| 87591 | Detection test by nucleic acid for neisseria gonorrhoeae (gonorrhoeae bacteria), amplified probe technique | Office | 2022 | 12 | 41 | $4,100 | $1,424 | 34.7% |
| 87536 | Detection test by nucleic acid for hiv-1 virus, quantification | Office | 2022 | 14 | 16 | $4,800 | $1,344 | 28.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 21 | $3,045 | $1,202 | 39.5% |
| 82652 | Dihydroxyvitamin d, 1, 25 level | Office | 2022 | 12 | 12 | $1,800 | $457.75 | 25.4% |
| 84403 | Testosterone (hormone) level, total | Office | 2022 | 11 | 12 | $1,020 | $304.78 | 29.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 21 | 26 | $3,250 | $271.28 | 8.3% |
| 86803 | Hepatitis c antibody measurement | Office | 2022 | 14 | 18 | $720.00 | $253.83 | 35.3% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2022 | 13 | 14 | $910.00 | $184.92 | 20.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 29 | 36 | $648.00 | $106.65 | 16.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 11 | 12 | $600.00 | $92.44 | 15.4% |
| 86592 | Syphilis detection test | Office | 2022 | 16 | 20 | $500.00 | $84.43 | 16.9% |
| 81003 | Automated urinalysis test | Office | 2022 | 19 | 25 | $875.00 | $55.53 | 6.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 21 | 27 | $4,995 | $2,324 | 46.5% |
| 87491 | Detection test by nucleic acid for chlamydia trachomatis, amplified probe technique | Office | 2021 | 15 | 61 | $6,100 | $2,140 | 35.1% |
About Dr. Anthony Mills, MD
Dr. Anthony Mills, MD is a Internal Medicine healthcare provider based in West Hollywood, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1679683049.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anthony Mills, MD has received a total of $510,976 in payments from pharmaceutical and medical device companies, with $12,089 received in 2024. These payments were reported across 852 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($226,957).
As a Medicare-enrolled provider, Mills has provided services to 1,142 Medicare beneficiaries, totaling 1,583 services with total Medicare billing of $41,574. Data is available for 4 years (2020–2023), covering 57 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location West Hollywood, CA
- Active Since 08/30/2006
- Last Updated 08/04/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1679683049
Products in Payments
- PREZISTA (Drug) $98,664
- Truvada (Drug) $33,757
- RUKOBIA (Drug) $26,243
- Biktarvy (Drug) $17,796
- CABENUVA (Biological) $17,205
- DELSTRIGO (Drug) $14,700
- DOVATO (Drug) $13,939
- TROGARZO (Drug) $12,742
- TIVICAY (Drug) $12,585
- EDURANT (Drug) $8,936
- Genvoya (Drug) $5,621
- TRIUMEQ (Drug) $5,342
- EPANOVA (Drug) $4,107
- SYMTUZA (Drug) $2,312
- SEROSTIM (Biological) $895.75
- PREZCOBIX (Drug) $767.34
- APRETUDE (Biological) $542.87
- ISENTRESS (Drug) $376.03
- Symtuza (Drug) $375.78
- INGREZZA (Drug) $337.15
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in West Hollywood
Dr. Andrew Hendifar, Md, Mph, MD, MPH
Internal Medicine — Payments: $290,268
Internal Medicine $290,268
Dr. Michael Shehata, M.d, M.D
Internal Medicine — Payments: $279,189
Internal Medicine $279,189
Dr. Stanley Jordan, Md, MD
Internal Medicine — Payments: $201,443
Internal Medicine $201,443
Dr. Barham Abu Dayyeh, Md, MD
Internal Medicine — Payments: $173,790
Internal Medicine $173,790
Dr. Rabindra Watson, M.d, M.D
Internal Medicine — Payments: $157,237
Internal Medicine $157,237
Phillip Gu, Md, MD
Internal Medicine — Payments: $80,698
Internal Medicine $80,698